RUNX3 is frequently inactivated in human cancers by promoter DNA hypermethylation [40,41,42,43,44,48,49,50,51,52,53], histone modification [54,55], hemizygous deletion [50,51], and protein mislocalisation [6,43]. Here, RUNX3 is linked to cancer.